Fig. 4From: Serum α-hydroxybutyrate dehydrogenase as a biomarker for predicting survival outcomes in patients with UTUC after radical nephroureterectomyDecision curve analysis of the nomogram about 3-year cancer-specific survival benefit (A) and 5-year cancer-specific survival benefit (B)Back to article page